Starten Sie Ihre Suche...


Durch die Nutzung unserer Webseite erklären Sie sich damit einverstanden, dass wir Cookies verwenden. Weitere Informationen
Publikationen
Ergebnisse pro Seite:  10

Michel, Martin C.; Staskin, David

Study Designs for Evaluation of Combination Treatment: Focus on Individual Patient Benefit

BIOMEDICINES. Bd. 10. H. 2. 2022


Penner, Inessa; Buescher, Nicole; Dejung, Mario et al.

Subviral Dense Bodies of Human Cytomegalovirus Induce an Antiviral Type I Interferon Response

CELLS. Bd. 11. H. 24. 2022




Stickdorn, Judith; Stein, Lara; Arnold-Schild, Danielle et al.

Systemically Administered TLR7/8 Agonist and Antigen-Conjugated Nanogels Govern Immune Responses against Tumors

ACS NANO. Bd. 16. H. 3. 2022 S. 4426-4443


Rampoldi, Francesca; Donato, Elisa; Ullrich, Leon et al.

T cells license immature B cells to produce a broad range of polyreactive antibodies

CELL REPORTS. Bd. 39. H. 8. 2022


Schwarzenbach, Christian; Tatsch, Larissa; Vilar, Juliana Brandstetter et al.

Targeting c-IAP1, c-IAP2, and Bcl-2 eliminates senescent glioblastoma cells following temozolomide treatment

ONCOLOGY RESEARCH AND TREATMENT. Bd. 45. H. SUPPL 3. 2022 S. 49-49


Winkler, Rene; Magdefrau, Ann-Sophie; Piskor, Eva-Maria et al.

Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibition

ONCOGENE. Bd. 41. H. 40. 2022 S. 4560-4572


Nandi, Tulika; Puonti, Oula; Clarke, William T. et al.

tDCS induced GABA change is associated with the simulated electric field in M1, an effect mediated by grey matter volume in the MRS voxel

BRAIN STIMULATION. Bd. 15. H. 5. 2022 S. 1153-1162


Kaina, Bernd; Beltzig, Lea; Strik, Herwig

Temozolomide - Just a Radiosensitizer?

FRONTIERS IN ONCOLOGY. Bd. 12. 2022